In 2024, Myriad Genetics was awarded three patents related to foundational platform MRD technology and cell-free DNA preparation methods that each enable highly sensitive and specific tumor-informed, ...

Myriad Genetics develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and tumor genomic testing and precision medicine, announced that the United States Patent and ...

Myriad Genetics announces USPTO grants two new patents for its molecular residual disease assay: Salt Lake City Friday, February 7, 2025, 13:00 Hrs [IST] Myriad Genetics, Inc., a ...

announced that the United States Patent and Trademark Office has issued two new patents that further advance Myriad's ability to bring its tumor-informed, high-definition, molecular residual disease ...

SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...

Sen. Bill Cassidy's intent to serve as a bulwark against Robert F. Kennedy Jr.'s vaccine skepticism may be sincere. But if Kennedy becomes the nation's top health official, Cassidy will have limited ...